A multicenter phase Ⅱ study of osimertinib plus infliximab in patients with EGFR-mutated non-small cell lung cancer positive for TP53 gain-of-function mutation who developed resistance to osimertinib (REGAIN trial)

JAAD International · Elsevier

Аннотация

Publication date: December 2026 Source: International Journal of Lung Cancer, Volume 1, Issue 4 Author(s): Eiji Iwama, Hiroshi Tanaka, Takehito Shukuya, Haruko Daga, Masayuki Takeda, Kentaro Tanaka, Eisaku Miyauchi, Yutaka Fujiwara, Nobuhisa Ishikawa, Koichi Azuma, Junko Tanizaki, Naoyuki Nogami, Jun Sakakibara-Konishi, Junji Umeno, Junji Kishimoto, Eiko Ishida, Isamu Okamoto

Читать у издателя →

Похожие статьи